<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34686150</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>405</StartPage><MedlinePgn>405</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">405</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-021-02438-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Compared with typical bulbar onset amyotrophic lateral sclerosis (ALS), isolated bulbar palsy (IBP), an often under-understood variant of ALS, is characterized by symptoms confined to bulbar region for extended periods and relative preservation of limb and ventilation function. To find a cutoff value of disease duration that can distinguish IBP from typical bulbar onset ALS well, the association of survival with disease progression in bulbar onset ALS patients was analyzed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Clinical data of bulbar onset ALS patients were collected from January 2009 to December 2013. The duration from bulbar onset to first significant limb involvement was analyzed by a cutoff point analysis with maximally selected log-rank statistics and dichotomized to categorize patient outcomes. The patients were divided into two groups, the IBP and typical bulbar onset ALS groups, according to the cutoff value. Clinical features were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">115 bulbar onset ALS patients were recruited, and the duration from bulbar onset to first significant limb involvement was associated with survival (P&#x2009;&lt;&#x2009;0.001). The cutoff duration was 20&#x2009;months. 19 patients were identified as IBP and 96 patients as typical bulbar onset ALS using 20&#x2009;months as the cutoff duration. Female was more common, limb weakness was less frequent and pure upper motor neuron (UMN) bulbar signs were more frequent in the IBP group than in the typical bulbar onset ALS group (P&#x2009;=&#x2009;0.047; P&#x2009;=&#x2009;0.004; P&#x2009;=&#x2009;0.031). The median survival time of the IBP group was significantly longer than that of the typical bulbar onset ALS group (64&#x2009;months and 26&#x2009;months, respectively; P&#x2009;&lt;&#x2009;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A cutoff duration of 20&#x2009;months from bulbar onset to first significant limb involvement may be used to specifically distinguish IBP from typical bulbar onset ALS. IBP was characterized by female predominance, relative preservation of limb function, more pure UMN bulbar signs and a relatively benign prognosis.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huagang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, No. 49, North Garden Road, Haidian District, Beijing, 100191, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, No. 49, North Garden Road, Haidian District, Beijing, 100191, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Jinzhou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Centre, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Dongsheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, No. 49, North Garden Road, Haidian District, Beijing, 100191, China. dsfan2010@aliyun.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative diseases, Beijing, China. dsfan2010@aliyun.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Neuroscience, National Health Commission/Ministry of Education, Peking University, Beijing, China. dsfan2010@aliyun.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010244" MajorTopicYN="Y">Bulbar Palsy, Progressive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Bulbar palsy</Keyword><Keyword MajorTopicYN="N">Motor neuron</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34686150</ArticleId><ArticleId IdType="pmc">PMC8532334</ArticleId><ArticleId IdType="doi">10.1186/s12883-021-02438-8</ArticleId><ArticleId IdType="pii">10.1186/s12883-021-02438-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82:740&#x2013;746. doi: 10.1136/jnnp.2010.235952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zhang B, Chen R, Tang L, Liu R, Yang Y, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry. 2015;86:1075&#x2013;1081. doi: 10.1136/jnnp-2015-310471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310471</ArticleId><ArticleId IdType="pubmed">26124198</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Vucic S, Kiernan MC. Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:283&#x2013;289. doi: 10.3109/17482968.2011.551940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.551940</ArticleId><ArticleId IdType="pubmed">21702735</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM. Amyotrophic lateral sclerosis regional variants (brachial amyotrophic diplegia, leg amyotrophic diplegia, and isolated bulbar amyotrophic lateral sclerosis) Neurol Clin. 2015;33:775&#x2013;785. doi: 10.1016/j.ncl.2015.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.003</ArticleId><ArticleId IdType="pmc">PMC4629514</ArticleId><ArticleId IdType="pubmed">26515621</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Breza M, Koutsis G. Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease. J Neurol. 2019;266:565&#x2013;573. doi: 10.1007/s00415-018-8968-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8968-7</ArticleId><ArticleId IdType="pubmed">30006721</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhan MA, et al. An Official American Thoracic Society/European Respiratory Society Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2015;192:1373&#x2013;1386. doi: 10.1164/rccm.201510-1966ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201510-1966ST</ArticleId><ArticleId IdType="pubmed">26623686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43:121&#x2013;137. doi: 10.1016/S0167-9473(02)00225-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-9473(02)00225-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HG, Chen L, Tang L, Zhang N, Fan DS. Clinical features of isolated bulbar palsy of amyotrophic lateral sclerosis in Chinese population. Chin Med J. 2017;1300:1768&#x2013;1772. doi: 10.4103/0366-6999.211538.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.211538</ArticleId><ArticleId IdType="pmc">PMC5547826</ArticleId><ArticleId IdType="pubmed">28748847</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T, Kitagawa K, Arai K. Phenotypic variability and its pathological basis in amyotrophic lateral sclerosis. Neuropathology. 2020;40:40&#x2013;56. doi: 10.1111/neup.12606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12606</ArticleId><ArticleId IdType="pubmed">31802540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromicho M, Figueiral M, Uysal H, Grosskreutz J, Kuzma-Kozakiewicz M, Pinto S, et al. Spreading in ALS: the relative impact of upper and lower motor neuron involvement. Ann Clin Transl Neurol. 2020;7:1181&#x2013;1192. doi: 10.1002/acn3.51098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51098</ArticleId><ArticleId IdType="pmc">PMC7359118</ArticleId><ArticleId IdType="pubmed">32558369</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>